Pulmonary complications of inflammatory myopathy.
Pulmonary manifestations contribute significantly to the morbidity and mortality of the idiopathic inflammatory myopathies, ranging from intrinsic lung disease to secondary complications that include aspiration pneumonia, opportunistic infection, congestive heart failure, and hypoventilation. Newer classification schemes for interstitial lung disease have permitted closer correlation between histologic subtype and clinical outcome, while diagnostic techniques such as bronchoalveolar lavage have begun to define the cellular elements responsible for immune-mediated pulmonary dysfunction. Investigators have identified several serum markers correlating with inflammatory disease activity in the lung that should enhance noninvasive monitoring of therapeutic responses to newer regimens involving agents such as cyclosporine and tacrolimus. Taken together, these advances have contributed to better understanding of the immunopathogenesis of myositis-associated interstitial lung disease that should ultimately translate into more effective treatment.
Ascherman
Dana P
DP
Division of Rheumatology and Clinical Immunology, University of Pittsburgh, S707 Biomedical Science Tower, 3500 Terrace Street, Pittsburgh, PA 15261, USA. ascher@pitt.edu
D018893:Bronchoalveolar Lavage; D003882:Dermatomyositis / Q000150:complications; D006801:Humans; D007633:Keratins / Q000097:blood; D008168:Lung / Q000276:immunology / Q000473:pathology*; D017563:Lung Diseases, Interstitial / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D017285:Polymyositis / Q000150:complications*; D014057:Tomography, X-Ray Computed
D007633:Keratins